Cannabinoid agonists inhibit neuropathic pain induced by brachial plexus avulsion in mice by affecting glial cells and MAP kinases

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Paszcuk, Ana F ^a   Dutra, Rafael C ^a   da Silva, Kathryn A B S ^a   Quintão, Nara L M ^b   Campos, Maria M ^c   Calixto, João B ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSIDADE DO VALE DO ITAJAÍ   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; ANALGESIC AGENT; BENZOXAZINE DERIVATIVE; CANNABINOID; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRACHIAL PLEXUS INJURY; CELL ACTIVATION; CHRONIC PAIN; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE SILENCING; GLIA CELL; IMMUNOHISTOCHEMISTRY; MECHANICAL ALLODYNIA; MICROGLIA; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINAL CORD; SPINAL GANGLION; ANIMAL; ANIMAL BEHAVIOR; BRACHIAL PLEXUS; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; GENETICS; GLIA; HYPERALGESIA; INJURY; METABOLISM; NEURALGIA; NOCICEPTION; PATHOLOGY; SIGNAL TRANSDUCTION; UPREGULATION;

MUS;

ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; BENZOXAZINES; BRACHIAL PLEXUS; CANNABINOIDS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; ENZYME ACTIVATION; FEMALE; GANGLIA, SPINAL; GENE KNOCKDOWN TECHNIQUES; HYPERALGESIA; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOLINES; NAPHTHALENES; NEURALGIA; NEUROGLIA; NF-KAPPA B; NOCICEPTION; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION; SPINAL CORD; UP-REGULATION;

EID: 80052729004     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024034     Document Type: Article

References (45)

1. Loeser JD, Treede RD, (2008) The Kyoto protocol of IASP Basic Pain Terminology. Pain 137: 473-477.
2. Dray A, (2008) Neuropathic pain: emerging treatments. Br J Anaesth 101: 48-58.
3. Hama A, Sagen J, (2007) Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury. Exp Neurol 204: 454-457.
4. Rahn EJ, Hohmann AG, (2009) Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherap 6: 713-737.
5. Hegyi Z, Kis G, Holló K, Ledent C, Antal M, (2009) Neuronal and glial localization of the cannabinoid-1 receptor in the superficial spinal dorsal horn of the rodent spinal cord. Eur J Neurosci 30: 251-262.
6. Hsieh GC, Pai M, Chandran P, Hooker BA, Zhu CZ, et al. (2011) Central and peripheral sites of action for CB2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol 162: 428-440.
7. Lim G, Sung B, Ji RR, Mao J, (2003) Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 105: 275-283.
8. Amaya F, Shimosato G, Kawasaki Y, Hashimoto S, Tanaka Y, et al. (2006) Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. Pain 124: 175-183.
9. Fernández-Ruiz J, Pazos MR, García-Arencibia M, Sagredo O, Ramos JA, (2008) Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol Cell Endocrinol 286: S91-96.
10. Romero-Sandoval A, Nutile-McMenemy N, DeLeo JA, (2008) Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiol 108: 722-734.
11. Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, Docagne F, Hagen C, et al. (2009) The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis 33: 57-71.
12. Songcharoen P, (2008) Management of brachial plexus injury in adults. Scand J Surg 97: 317-323.
13. Milligan ED, Watkins LR, (2009) Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 10: 23-36.
14. Stella N, (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58: 1017-1030.
15. Chang YW, Waxman SG, (2010) Minocycline Attenuates Mechanical Allodynia and Central Sensitization Following Peripheral Second-Degree Burn Injury. J Pain 11: 1146-1154.
16. Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Koizumi S, Inoue K, (2004) Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 45: 89-95.
17. Zhuang ZY, Wen YR, Zhang DR, Borsello T, Bonny C, et al. (2006) A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci 26: 3551-3560.
18. Howlett AC, (2005) Cannabinoid receptor signalling. Handb Exp Pharmacol 168: 53-79.
19. Ma W, Quirion R, (2001) Increased phosphorylation of cyclic AMP response element-binding protein (CREB) in the superficial dorsal horn neurons following partial sciatic nerve ligation. Pain 93: 295-301.
20. Qin ZH, Tao LY, Chen X, (2007) Dual roles of NF-kappaB in cell survival and implications of NF-kappaB inhibitors in neuroprotective therapy. Acta Pharmacol Sin 28: 1859-1872.
21. Wen AY, Sakamoto KM, Miller LS, (2010) The role of the transcription factor CREB in immune function. J Immunol 185: 6413-6419.
22. Bromberg KD, Ma'ayan A, Neves SR, Iyengar R, (2008) Design logic of a cannabinoid receptor signaling network that triggers neurite outgrowth. Science 320: 903-909.
23. Zorina Y, Iyengar R, Bromberg KD, (2010) Cannabinoid 1 receptor and interleukin-6 receptor together induce integration of protein kinase and transcription factor signaling to trigger neurite outgrowth. J Biol Chem 285: 1358-1370.
24. Gutierrez H, O'Keeffe GW, Gavaldà N, Gallagher D, Davies AM, (2008) Nuclear factor kappa B signaling either stimulates or inhibits neurite growth depending on the phosphorylation status of p65/RelA. J Neurosci 28: 8246-8256.
25. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, et al. (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10: 870-879.
26. Yamamoto W, Mikami T, Iwamura H, (2008) Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. Eur J Pharmacol 583: 56-61.
27. Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, et al. (2005) Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49: 211-219.
28. Richardson JD, Aanonsen L, Hargreaves KM, (1998) Hypoactivity of the Spinal Cannabinoid System Results in NMDA-Dependent Hyperalgesia. J Neurosci 18: 451-457.
29. Dogrul A, Gardell LR, Ma S, Michael H, Ossipov MH, et al. (2002) 'Knock-down' of spinal CB1 receptors produces abnormal pain and elevates spinal dynorphin content in mice. Pain 100: 203-209.
30. Stone LS, Vulchanova L, (2003) The pain of antisense: in vivo application of antisense oligonucleotides for functional genomics in pain and analgesia. Adv Drug Deliv Rev 55: 1081-1112.
31. Kurreck J, (2004) Antisense and RNA interference approaches to target validation in pain research. Curr Opin Drug Discov Devel 7: 179-187.
32. Myers KJ, Dean NM, (2000) Sensible use of antisense: how to use oligonucleotides as research tools. Trends Pharmacol Sci 21: 19-23.
33. Eder PS, DeVine RJ, Dagle JM, Walder JA, (1991) Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res Dev 1: 141-51.
34. Walder RY, Walder JA, (1988) Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci U S A 85: 5011-5015.
35. Kanaya S, Ikehara M, (1995) Functions and structures of ribonuclease H enzymes. Subcell Biochem 24: 377-422.
36. Zimmermann M, (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110.
37. Quintão NL, Santos AR, Campos MM, Calixto JB, (2008) The role of neurotrophic factors in genesis and maintenance of mechanical hyperalgesia after brachial plexus avulsion in mice. Pain 136: 125-133.
38. Quintão NL, Passos GF, Medeiros R, Paszcuk AF, Motta FL, et al. (2008) Neuropathic pain-like behavior after brachial plexus avulsion in mice: the relevance of kinin B1 and B2 receptors. J Neurosci 28: 2856-2863.
39. Yoon MH, Choi JI, (2003) Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test. Anesthesiol 99: 701-707.
40. Doǧrul A, Gül H, Yildiz O, Bilgin F, Güzeldemir ME, (2004) Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett 368: 82-86.
41. Sanson M, Bueno L, Fioramonti J, (2006) Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil 18: 949-956.
42. Bahremand A, Shafaroodi H, Ghasemi M, Nasrabady SE, Gholizadeh S, et al. (2008) The cannabinoid anticonvulsant effect on pentylenetetrazole-induced seizure is potentiated by ultra-low dose naltrexone in mice. Epilepsy Res 81: 44-51.
43. Potenzieri C, Brink TS, Pacharinsak C, Simone DA, (2008) Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation. J Neurophysiol 100: 2794-2806.
44. Hylden JL, Wilcox GL, (1980) Intrathecal morphine in mice: a new technique. Eur J Pharmacol 67: 313-316.
45. Laursen SE, Belknap JK, (1986) Intracerebroventricular injections in mice: some methodological refinements. J Pharmacol Methods 16: 355-357.